1. Home
  2. CCHH vs BIVI Comparison

CCHH vs BIVI Comparison

Compare CCHH & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCHH

CCH Holdings Ltd Ordinary Shares

HOLD

Current Price

$0.37

Market Cap

13.9M

Sector

N/A

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.60

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCHH
BIVI
Founded
2015
2013
Country
Malaysia
United States
Employees
207
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
11.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CCHH
BIVI
Price
$0.37
$1.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
63.9K
106.8K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$43.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.88
52 Week High
$15.39
$9.09

Technical Indicators

Market Signals
Indicator
CCHH
BIVI
Relative Strength Index (RSI) 36.46 57.50
Support Level $0.36 $1.17
Resistance Level $0.52 $1.71
Average True Range (ATR) 0.04 0.14
MACD -0.00 0.03
Stochastic Oscillator 0.47 68.75

Price Performance

Historical Comparison
CCHH
BIVI

About CCHH CCH Holdings Ltd Ordinary Shares

CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: